Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E, León A, Grávalos C, Cámara JC, Feliú J, Sanchíz B, Caldés T, Díaz-Rubio E. Llovet P, et al. Mol Diagn Ther. 2015 Dec;19(6):397-408. doi: 10.1007/s40291-015-0165-0. Mol Diagn Ther. 2015. PMID: 26341080
Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
Trojan J, Mineur L, Tomášek J, Rouleau E, Fabian P, de Maglio G, García-Alfonso P, Aprile G, Taylor A, Kafatos G, Downey G, Terwey JH, van Krieken JH. Trojan J, et al. PLoS One. 2015 Oct 22;10(10):e0140717. doi: 10.1371/journal.pone.0140717. eCollection 2015. PLoS One. 2015. PMID: 26491871 Free PMC article.
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Borrero-Palacios A, et al. Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Sci Rep. 2019. PMID: 30796344 Free PMC article. Clinical Trial.
Oral drugs in the treatment of metastatic colorectal cancer.
García-Alfonso P, Muñoz Martín AJ, Ortega Morán L, Soto Alsar J, Torres Pérez-Solero G, Blanco Codesido M, Calvo Ferrandiz PA, Grasso Cicala S. García-Alfonso P, et al. Ther Adv Med Oncol. 2021 Apr 29;13:17588359211009001. doi: 10.1177/17588359211009001. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33995592 Free PMC article. Review.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Kubicka S, et al. Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12. Ann Oncol. 2013. PMID: 23852309 Free article. Clinical Trial.
160 results